Transplantation is an Option for Aggressive Lymphoma Patients w DLBL or High-Grade Lymphoma can benefit
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains Transplantation is an Option for Aggressive Lymphoma Patients w DLBL or High-Grade Lymphoma can benefit at Imedex Great Debates 2018.
Author: hematologydebates
Added: 04/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 19, 2018 Category: Cancer & Oncology Source Type: podcasts
25% of Patients Relapse Early in Follicular Lymphoma New targeted agents changes approach to patients
Grzegorz S. Nowakowski, M.D., Mayo Clinic, explains 25% of Patients Relapse Early in Follicular Lymphoma New targeted agents changes approach to patients at Imedex Great Debates 2018.
Author: hematologydebates
Added: 04/19/2018 (Source: Oncology Tube)
Source: Oncology Tube - April 19, 2018 Category: Cancer & Oncology Source Type: podcasts
PEP-C for lymphoma palliative care: a regional experience in the UK
Treating lymphoma patients in the relapsed/refractory setting often proves a challenge for physicians. PEP-C (prednisolone, etoposide, procarbazine and cyclophosphamide) is a chemotherapy regimen used...
Author: VJHemOnc
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
ABVD vs. escBEACOPP in HL: a 10-year study
In the UK, escalated BEACOPP (escBEACOPP) was introduced as an alternative to ABVD for the treatment of advanced-stage Hodgkin lymphoma (HL). Here, George Follows, BMBCh, PhD, FRCP, FRCPath, of Cambri...
Author: VJHemOnc
Added: 02/09/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 9, 2018 Category: Cancer & Oncology Source Type: podcasts
Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who failed initial therapy
Elizabeth Brm, MD - HS Clinical Assistant Professor Chao Comprehensive Cancer Center discusses Rituximab Maintenance for Follicular Lymphoma CAR-T Trial salvages Primary, Refractory, or those who fai...
Author: moasc
Added: 02/06/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 7, 2018 Category: Cancer & Oncology Source Type: podcasts
Highlights of ASH 2017 Lymphomas
Elizabeth Brm, MD, from The Chao Comprehensive Cancer Center joins us at MOASCs Spotlight On Hematology in Huntington Beach to present some of the highlights of ASH 2017 Lymphomas.
Author: moasc
Added: 02/01/2018 (Source: Oncology Tube)
Source: Oncology Tube - February 2, 2018 Category: Cancer & Oncology Source Type: podcasts
Comparing CAR T-Cell Therapies in Lymphoma
Drs Ann LaCasce and Caron Jacobson on how these and other treatments may change your practice in the new year. (Source: Medscape Oncology)
Source: Medscape Oncology - January 29, 2018 Category: Cancer & Oncology Authors: Medscape Source Type: podcasts
CAR-T Cell Therapy in Large Cell Lymphoma 80response rate with 50complete remission
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses CAR-T cell therapy in large cell Lymphoma - 80 response rate with 50 complete remission at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2018 Category: Cancer & Oncology Source Type: podcasts
CAR-T Cell Therapy in Large Cell Lymphoma - 80 response rate with 50 complete remission
Sattva S. Neelapu, MD from MD Anderson Cancer Center discusses CAR-T cell therapy in large cell Lymphoma - 80 response rate with 50 complete remission at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/12/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 12, 2018 Category: Cancer & Oncology Source Type: podcasts
Progress has been made combatting Hodgkins lymphoma - A more effective recipe new analyses and insights for treatments
Joseph M. Connors, MD from British Colombia Cancer Agency discusses the progress that has been made combatting Hodgkins lymphoma and a more effective recipe new analyses and insights for treatments at...
Author: ASHReport
Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Atezolizumab + Bendamustine & Obinutuzumab - No major safety signals in follicular lymphoma
John M. Burke, MD from Rocky Mountain Cancer Centers discusses Atezolizumab + Bendamustine & Obinutuzumab and no major safety signals in follicular lymphoma at the 2017 American Society of Hematology.
Author: ASHReport
Added: 01/11/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 11, 2018 Category: Cancer & Oncology Source Type: podcasts
Axi-Cel is a milestone for treating B-Cell Lymphoma Paradigm shift for future B-Cell Lymphoma treatment
Sattva S. Neelapu, MD, from the University of Texas MD Anderson Cancer Center discusses how Axi-Cel is a milestone for treating B-Cell Lymphoma and the paradigm shift for future B-Cell Lymphoma treatm...
Author: ASHReport
Added: 01/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Checkpoint Inhibitors in Hodgkin's Lymphoma - Immune System Manipulation and CAR-T Cells
Joseph M. Connors, MD, FRCPC from The BC Cancer Agency Research Centre discusses checkpoint inhibitors in Hodgkin's lymphoma and immune system manipulation and car-t cells at the 2017 American Society...
Author: ASHReport
Added: 01/10/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 10, 2018 Category: Cancer & Oncology Source Type: podcasts
Antagomir for cutaneous T-cell lymphoma: promising trial results
In cutaneous T-cell lymphoma (CTCL) miR-155 has been shown to be upregulated. Here, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses an antogomir being developed to target this var...
Author: VJHemOnc
Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts
Immune checkpoint inhibitors for cutaneous T-cell lymphoma
Immune checkpoint inhibitors have now entered the treatment landscape for cutaneous T-cell lymphoma (CTCL). In this interview, Christiane Querfeld, MD, PhD, of City of Hope, Duarte, CA, discusses a Ph...
Author: VJHemOnc
Added: 01/08/2018 (Source: Oncology Tube)
Source: Oncology Tube - January 8, 2018 Category: Cancer & Oncology Source Type: podcasts
